Stock NGNE NEUROGENE INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Neurogene Inc.

Equities

NGNE

US64135M1053

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
37.6 USD +10.10% Intraday chart for Neurogene Inc. +17.10% +94.01%
May. 10 Neurogene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
May. 07 Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of Ngn-401 Gene Therapy for Rett Syndrome During Asgct Annual Meeting CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates
AQ
Neurogene: Q1 Earnings Snapshot
AQ
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates
BU
Neurogene : ASGCT NGN-401 Clinical Safety Poster
PU
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting
BU
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
BU
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates
BU
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial
BU
Neurogene to Participate in Upcoming Investor Conferences
BU
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer
BU
Neurogene Announces Business Update and 2024 Outlook
BU
Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million
AQ
Neoleukin Therapeutics : Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome - Form 8-K
PU
Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
AQ
Neoleukin: Q3 Earnings Snapshot
AQ
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
GL
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
AQ
NEOLEUKIN THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Neoleukin Therapeutics, Inc. - NLTX
BU
Shareholder Alert: Ademi LLP investigates whether Neoleukin Therapeutics, Inc. has obtained a Fair Price in its Private Placement and its transaction with Neurogene
PR
NLTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Neoleukin Therapeutics, Inc. Is Fair to Shareholders
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NGNE Stock
  4. News Neurogene Inc.
  5. Press Releases